Adagene (ADAG) vs Satellos Bioscience (MSLE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Adagene (ADAG) has outperformed Satellos Bioscience (MSLE) over the past year, gaining 42.2% versus a gain of 7.4%. Over five years, MSLE leads with a -50.8% price change compared with -76.2% for ADAG. Adagene is the larger company by market cap ($179.3 million vs $160.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | MSLE |
|---|---|---|
| Share price | $2.67 | $7.54 |
| Market cap | $179.27M | $159.97M |
| 1-day change | -3.96% | +2.65% |
| YTD return | +47.09% | +24.91% |
| 1-year return | +42.20% | +7.38% |
| 5-year return | -76.24% | -50.84% |
| EPS (TTM) | $-0.37 | $-1.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.85 | $13.40 |
| 52-week low | $1.30 | $5.30 |
| Distance from 52-week high | -44.95% | -43.71% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +271.16% | +242.18% |
| Average volume | 244.76K | 50.10K |
| Shares outstanding | 67.14M | 21.22M |
| Employees | 128 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed MSLE by 34.8 percentage points over the past year.
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
ADAG vs MSLE FAQ
Which is bigger, Adagene or Satellos Bioscience?
Adagene (ADAG) is larger, with a market capitalization of $179.27M compared with $159.97M for Satellos Bioscience (MSLE).
Which stock has performed better over the past year, ADAG or MSLE?
ADAG returned +42.20% over the past 12 months, compared with +7.38% for MSLE (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and Satellos Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.